ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
Status:
Active, not recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness of repurposed medications (study
drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19.
Participants will receive either study drug or placebo. Participants will self-report any new
or worsening symptoms or medical events experienced while taking study drug or placebo. This
study is intended to be all remote with no in person visits, unless the study team feels it
is in the best interest of a participant to be seen in person.
Prior and current drug arms are listed on clinicaltrials.gov and will be updated with the
activation of any new drug arms. Each study arm will also have its own clinicaltrials.gov
entry and will include "Pro00107921" in the Unique Protocol ID.
Phase:
Phase 3
Details
Lead Sponsor:
Susanna Naggie, MD
Collaborators:
National Center for Advancing Translational Sciences (NCATS) Vanderbilt University Medical Center